Drug Combo Targets HIV In CNS

15 October 1997

Treatment with Abbott Laboratories' Norvir (ritonavir) and Hoffmann-LaRoche's Invirase (saquinavir mesylate) resulted in undetectable levels of HIV (less than 400 copies/mL) in the cerebrospinal fluid of patients, according to data reported at ICAAC.

The data come from an open-label study which randomized 141 protease inhibitor-naive HIV-positive patients to one of four different treatment arms. After 48 weeks, 90% of the 109 evaluable patients had undetectable plasma HIV RNA (less than 200 copies/mL). 13 patients who experienced this level of viral suppression after 60 weeks had CSF analysis performed and 12 had undetectable HIV RNA in their CSF (less than 400 copies/mL).

Brain A Viral Sanctuary? Although the clinical significance of virus levels in CSF is unknown, another studydiscussed the relationship between CSF and the severity of AIDS-related dementia. Justin McArthur, professor of neurology at Johns Hopkins University, studied 207 HIV-positive patients and found that virus levels in the CSF were significantly higher amongst those with AIDS-related dementia. These data suggest that the virus has a causal role in the development of this condition, he said. Most available drugs for HIV infection suffer from very poor central nervous system penetration.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight